Evidence-Based Cytopathology: A Call for Implementation.

IF 1.1 4区 医学 Q4 CELL BIOLOGY
Cytopathology Pub Date : 2025-09-21 DOI:10.1111/cyt.70024
Guido Muharremi, Visar Vela, Philippe Vielh, Taulant Muka
{"title":"Evidence-Based Cytopathology: A Call for Implementation.","authors":"Guido Muharremi, Visar Vela, Philippe Vielh, Taulant Muka","doi":"10.1111/cyt.70024","DOIUrl":null,"url":null,"abstract":"<p><p>Evidence-based medicine (EBM) emerged in the mid-1990s as a systematic and data-driven approach to clinical practice. It plays a crucial role in cytopathology, which focuses on identifying both neoplastic and non-neoplastic disorders. Despite its importance, cytopathology faces significant challenges in implementing EBM principles. These include diagnostic variability, interobserver discrepancies, and subjective interpretations, which can impact diagnostic consistency and patient outcomes. These issues often lead to inconsistencies in diagnosis, underdiagnosis, or overdiagnosis, ultimately compromising patient outcomes. To address these challenges, evidence-based cytopathology (EBC) emphasises the critical evaluation of diagnostic tests and the utilisation of well-designed and high-quality data to establish robust guidelines. EBC promotes the adoption of standardised diagnostic criteria, integrates robust study designs with the implementation of advanced technologies like artificial intelligence (AI), and leverages clinical decision support systems (CDSS) to enhance diagnostic accuracy and consistency. However, realising the full benefits of EBC requires collaborative research, multicenter trials, and continuous updates to guidelines. In this paper, we discuss the future efforts in improving EBC outcomes, with a focus on developing precise diagnostic instruments, refining methodologies, and exploring machine learning applications to improve diagnostic reliability, enhance patient care, and support informed clinical decision-making.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cyt.70024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Evidence-based medicine (EBM) emerged in the mid-1990s as a systematic and data-driven approach to clinical practice. It plays a crucial role in cytopathology, which focuses on identifying both neoplastic and non-neoplastic disorders. Despite its importance, cytopathology faces significant challenges in implementing EBM principles. These include diagnostic variability, interobserver discrepancies, and subjective interpretations, which can impact diagnostic consistency and patient outcomes. These issues often lead to inconsistencies in diagnosis, underdiagnosis, or overdiagnosis, ultimately compromising patient outcomes. To address these challenges, evidence-based cytopathology (EBC) emphasises the critical evaluation of diagnostic tests and the utilisation of well-designed and high-quality data to establish robust guidelines. EBC promotes the adoption of standardised diagnostic criteria, integrates robust study designs with the implementation of advanced technologies like artificial intelligence (AI), and leverages clinical decision support systems (CDSS) to enhance diagnostic accuracy and consistency. However, realising the full benefits of EBC requires collaborative research, multicenter trials, and continuous updates to guidelines. In this paper, we discuss the future efforts in improving EBC outcomes, with a focus on developing precise diagnostic instruments, refining methodologies, and exploring machine learning applications to improve diagnostic reliability, enhance patient care, and support informed clinical decision-making.

基于证据的细胞病理学:呼吁实施。
循证医学(EBM)出现于20世纪90年代中期,是一种系统的、数据驱动的临床实践方法。它在细胞病理学中起着至关重要的作用,细胞病理学的重点是识别肿瘤和非肿瘤疾病。尽管它很重要,但细胞病理学在实施循证医学原则方面面临着重大挑战。这些因素包括诊断的可变性、观察者之间的差异和主观解释,这些都会影响诊断的一致性和患者的预后。这些问题往往导致诊断不一致、诊断不足或过度诊断,最终损害患者的预后。为了应对这些挑战,基于证据的细胞病理学(EBC)强调对诊断测试进行批判性评估,并利用精心设计的高质量数据来制定强有力的指南。EBC促进标准化诊断标准的采用,将稳健的研究设计与人工智能(AI)等先进技术的实施相结合,并利用临床决策支持系统(CDSS)来提高诊断的准确性和一致性。然而,实现EBC的全部益处需要合作研究、多中心试验和不断更新指南。在本文中,我们讨论了改善EBC结果的未来努力,重点是开发精确的诊断仪器,改进方法,探索机器学习应用,以提高诊断可靠性,加强患者护理,并支持知情的临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cytopathology
Cytopathology 生物-病理学
CiteScore
2.30
自引率
15.40%
发文量
107
审稿时长
6-12 weeks
期刊介绍: The aim of Cytopathology is to publish articles relating to those aspects of cytology which will increase our knowledge and understanding of the aetiology, diagnosis and management of human disease. It contains original articles and critical reviews on all aspects of clinical cytology in its broadest sense, including: gynaecological and non-gynaecological cytology; fine needle aspiration and screening strategy. Cytopathology welcomes papers and articles on: ultrastructural, histochemical and immunocytochemical studies of the cell; quantitative cytology and DNA hybridization as applied to cytological material.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信